{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T07:29:42Z","timestamp":1785914982212,"version":"3.56.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.intimp.2022.108952","type":"journal-article","created":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T18:51:02Z","timestamp":1655319062000},"page":"108952","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Pamidronate, a promising repositioning drug to treat leishmaniasis, displays antileishmanial and immunomodulatory potential"],"prefix":"10.1016","volume":"110","author":[{"given":"Juliana M.","family":"Ribeiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina L.","family":"Rodrigues-Alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro P.G.","family":"Guimar\u00e3es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Maria Murta Santi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Teixeira-Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvane M.F.","family":"Murta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Peruhype-Magalh\u00e3es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine M.","family":"Souza-Fagundes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2022.108952_b0005","unstructured":"WHO, World Health Organization. Available from: <https:\/\/www.who.int\/health-topics\/leishmaniasis> (Accessed June 08, 2021)."},{"key":"10.1016\/j.intimp.2022.108952_b0010","doi-asserted-by":"crossref","unstructured":"B. Burza, S.L. Croft, M. Boelaert, Leishmaniasis, The Lancet (2018) 951-970. 10.1016\/S0140-6736(18)31204-2.","DOI":"10.1016\/S0140-6736(18)31204-2"},{"key":"10.1016\/j.intimp.2022.108952_b0015","doi-asserted-by":"crossref","unstructured":"P.J. Guerin, P. Olliaro, S. Sundar, M. Boelart, S.L. Croft, P. Desjeux, M.K. Wasunna, A.D.M. Bryceson, Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda, The Lancet Infectious Diseases (2002) 494-501. 10.1016\/s1473-3099(02)00347-x.","DOI":"10.1016\/S1473-3099(02)00347-X"},{"key":"10.1016\/j.intimp.2022.108952_b0020","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.1365-3083.2005.01686.x","article-title":"Immune response in human visceral leishmaniasis: Analysis of the correlation between innate immunity cytokine profile and disease outcome","author":"Peruhype-Magalh\u00e3es","year":"2005","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.intimp.2022.108952_b0025","doi-asserted-by":"crossref","unstructured":"C. dos S. Meira, L. Gedamu, Protective or detrimental? Understanding the role of host immunity in leishmaniasis, Microorganisms (2019), e695. 10.3390\/microorganisms7120695.","DOI":"10.3390\/microorganisms7120695"},{"key":"10.1016\/j.intimp.2022.108952_b0030","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00670","article-title":"Cytokines: Key determinants of resistance or disease progression in visceral leishmaniasis: Opportunities for novel diagnostics and immunotherapy","author":"Dayakar","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2022.108952_b0035","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1111\/cmi.12484","article-title":"Innate immunity against Leishmania infections","author":"Gurung","year":"2015","journal-title":"Cell Microbiology"},{"key":"10.1016\/j.intimp.2022.108952_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.108745","article-title":"Quercetin promotes antipromastigote effect by increasing the ROS production and anti-amastigote by upregulating Nrf2\/HO-1 expression, affecting iron availability","author":"Caetano","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.intimp.2022.108952_b0045","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1017\/S0031182017000993","article-title":"Repurposing as a strategy for the discovery of new anti-leishmanial: the-state-of-the-art","author":"Charlton","year":"2018","journal-title":"Parasitology"},{"issue":"70","key":"10.1016\/j.intimp.2022.108952_b0050","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1590\/S0103-40142010000300006","article-title":"Planejamento de f\u00e1rmacos, biotecnologia e qu\u00edmica medicinal: aplica\u00e7\u00f5es em doen\u00e7as infecciosas","volume":"24","author":"Guido","year":"2010","journal-title":"Estudos Avan\u00e7ados"},{"key":"10.1016\/j.intimp.2022.108952_b0055","doi-asserted-by":"crossref","unstructured":"H.W. Murray, Treatment for visceral leishmaniasis in 2010: direction for Bihar state, India, Future Microbiol. (2010) 1301-1303. https:\/\/doi.org\/10.2217\/fmb.10.92.","DOI":"10.2217\/fmb.10.92"},{"key":"10.1016\/j.intimp.2022.108952_b0060","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.7150\/ijbs.24612","article-title":"Review of drug repositioning approaches and resources","author":"Xue","year":"2018","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.intimp.2022.108952_b0065","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1111\/jphp.13273","article-title":"Drug repositioning: a brief overview","author":"Jourdan","year":"2020","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.intimp.2022.108952_b0070","first-page":"41","article-title":"Drug repurposing: Progress, challenges, and recommendations","author":"Pushpakom","year":"2018","journal-title":"Nat. Rev. Drug Discovery"},{"key":"10.1016\/j.intimp.2022.108952_b0075","first-page":"1","article-title":"Insights about the structure of farnesyl diphosphate synthase (FPPS) and the activity of bisphosphonates on the proliferation and ultrastructure of Leishmania and Giardia","author":"Gadelha","year":"2020","journal-title":"Parasites Vectors"},{"key":"10.1016\/j.intimp.2022.108952_b0080","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1021\/jm0002578","article-title":"Bisphosphonates inhibit the growth of Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondii, and Plasmodium falciparum: A potential route to chemotherapy","author":"Martin","year":"2001","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.intimp.2022.108952_b0085","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1128\/AAC.46.3.929-931.2002","article-title":"In vivo activities of farnesyl pyrophosphate synthase inhibitors against Leishmania donovani and Toxoplasma gondii","author":"Yardley","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.intimp.2022.108952_b0090","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.ijantimicag.2003.07.020","article-title":"Selective in vitro effects of the farnesyl pyrophosphate synthase inhibitor risedronate on Trypanosoma cruzi","author":"Garzoni","year":"2004","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.intimp.2022.108952_b0095","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s00436-005-1331-9","article-title":"Risedronate in the treatment of Murine Chagas\u2019 disease","author":"Bouzahzah","year":"2005","journal-title":"Parasitol. Res."},{"key":"10.1016\/j.intimp.2022.108952_b0100","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1086\/341074","article-title":"Radical cure of experimental cutaneous leishmaniasis by the bisphosphonate pamidronate","author":"Rodriguez","year":"2002","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.intimp.2022.108952_b0105","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-30076-7","article-title":"Growth arrested live-attenuated Leishmania infantum KHARON1 null mutants display cytokinesis defect and protective immunity in mice","author":"Santi","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.intimp.2022.108952_b0110","doi-asserted-by":"crossref","unstructured":"J.M. Ribeiro, C.C. Bandeira, B.G. de Faria, M.L.R. alves, F.O. Vieira, R.C. Giunchetti, J.E. Uzonna, A. Teixeira-Carvalho, V. Peruhype-Magalh\u00e3es, E.M. Souza-Fagundes, An ex vivo multiparametric flow cytometry assay using human whole blood to simultaneously measure cytotoxicity and leishmanicidal activities, Exp. ParasitoL. (2020), e107940. 10.1016\/j.exppara.2020.107940.","DOI":"10.1016\/j.exppara.2020.107940"},{"key":"10.1016\/j.intimp.2022.108952_b0115","doi-asserted-by":"crossref","first-page":"321","DOI":"10.4103\/0019-5154.156416","article-title":"Evaluation of organelle changes in promastigotes of unresponsive Leishmania tropica to meglumine antimoniate in comparison with sensitive and standard isolates by electron microscopy","author":"Bahreini","year":"2015","journal-title":"Indian J. Dermatol."},{"key":"10.1016\/j.intimp.2022.108952_b0120","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/nrd2144","article-title":"Innovative lead discovery strategies for tropical diseases","author":"Nwaka","year":"2006","journal-title":"Nat. Rev. Drug Discovery"},{"key":"10.1016\/j.intimp.2022.108952_b0125","doi-asserted-by":"crossref","unstructured":"G.E.M. Ferreira, B.N. Santos, M.E.C. Dorval, T.P.B. Ramos, R. Porrozzi, A.A. Peixoto, E. Cupolillo, The genetic structure of Leishmania infantum populations in Brazil and its possible association with the transmission cycle of visceral leishmaniasis, Plos One (2012), e36242. 10.1371\/journal.pone.0036242.","DOI":"10.1371\/journal.pone.0036242"},{"key":"10.1016\/j.intimp.2022.108952_b0130","doi-asserted-by":"crossref","unstructured":"J.A. Urbina, B. Moreno, S. Vierkotter, E. Oldfield, G. Payares, C. Sanoja, B.N. Baileym W. Yan, D.A. Scott, S.N.J. Moreno, R. Docampo, Trypanosoma cruzi contains major pyrophosphate stores, and its growth in vitro and in vivo is blocked by pyrophosphate analogs, J. Biol. Chem. (1999) 33609-33615. 10.1074\/jbc.274.47.33609.","DOI":"10.1074\/jbc.274.47.33609"},{"key":"10.1016\/j.intimp.2022.108952_b0135","doi-asserted-by":"crossref","first-page":"33930","DOI":"10.1074\/jbc.M103950200","article-title":"Bisphosphonates are potent inhibitors of Trypanosoma cruzi farnesyl pyrophosphate synthase","author":"Montalvetti","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.intimp.2022.108952_b0140","doi-asserted-by":"crossref","first-page":"5171","DOI":"10.1021\/jm0302344","article-title":"3-D QSAR Investigations of the Inhibition of Leishmania major Farnesyl Pyrophosphate Synthase by Bisphosphonates","author":"Sanders","year":"2003","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.intimp.2022.108952_b0145","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/wsbm.32","article-title":"Role of neutrophils in innate immunity: a systems biology\u2010level approach","volume":"1","author":"Kobayashi","year":"2009","journal-title":"WIREs Mechanisms of Disease"},{"key":"10.1016\/j.intimp.2022.108952_b0150","article-title":"Immune response to Leishmania infection","volume":"238\u2013258","author":"Awasthi","year":"2004","journal-title":"Indian J. Med. Res."},{"key":"10.1016\/j.intimp.2022.108952_b0155","first-page":"224","article-title":"In vitro leishmanicidal activity of lactone 1,4-dihydroquinoline derivates against Leishmania (Leishmania) amazonensis","author":"Pissurno","year":"2018","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.intimp.2022.108952_b0160","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1002\/jbmr.5650111015","article-title":"Bisphosphonates induce apoptosis in mouse macrophage-like cells in vitro by a nitric oxide-independent mechanism","author":"Rogers","year":"1996","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.intimp.2022.108952_b0165","first-page":"8037","article-title":"Signaling Pathways of Apoptosis Activated by Aromatase Inhibitors and Antiestrogens","author":"Thiantanawat","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.intimp.2022.108952_b0170","first-page":"34","article-title":"The pharmacology of letrozole","author":"Haynes","year":"2003","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.intimp.2022.108952_b0175","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s10549-007-9696-3","article-title":"The discovery and mechanism of action of letrozole","author":"Bhatnagar","year":"2007","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.intimp.2022.108952_b0180","doi-asserted-by":"crossref","unstructured":"A.K. Dunbier, Z. Ghazoui, H. Anderson, J. Salter, A. Nerurkar, P. Osin, R. A'hern, W.R. Miller, I.E. Smith, M. Dowsett, Molecular profiling of aromatase inhibitor-treated postmenopausal breast tumors identifies immune-related correlates of resistance, Clin. Cancer Res. (2013) 2775\u20132786. 10.1158\/1078-0432.CCR-12-1000.","DOI":"10.1158\/1078-0432.CCR-12-1000"},{"key":"10.1016\/j.intimp.2022.108952_b0185","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0101260","article-title":"Macrophage depletion by free bisphosphonates and Zoledronate-loaded red blood cells","author":"Sabatino","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.intimp.2022.108952_b0190","doi-asserted-by":"crossref","unstructured":"R.G.G. Russel, Bisphosphonates: Mode of Action and Pharmacology, Pediatrics (2007). 10.1542\/peds.2006-2023H.","DOI":"10.1542\/peds.2006-2023H"},{"key":"10.1016\/j.intimp.2022.108952_b0195","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1128\/EC.00034-06","article-title":"Farnesyl diphosphate synthase is a cytosolic enzyme in Leishmania major promastigotes and its overexpression confers resistance to risedronate","author":"\u00d3rtiz-G\u00f3mez","year":"2006","journal-title":"Eukaryot. Cell"},{"key":"10.1016\/j.intimp.2022.108952_b0200","first-page":"380","article-title":"Investigating changes in monocyte phenotypes and functions in active visceral leishmaniasis patients","author":"Singh","year":"2016","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.intimp.2022.108952_b0205","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.01896","article-title":"Infection of human monocytes with Leishmania infantum strains induces a downmodulated response when compared with infection with Leishmania braziliensis","author":"Viana","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2022.108952_b0210","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1038\/ni1102-1041","article-title":"Evasion of innate immunity by parasitic protozoa","author":"Sacks","year":"2002","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.intimp.2022.108952_b0215","first-page":"1","article-title":"The involvement of TLR2 and TLR4 in cytokine and nitric oxide production in visceral leishmaniasis patients before and after treatment with anti-leishmanial drugs","author":"Gatto","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.intimp.2022.108952_b0220","article-title":"Nanoliposomal Buparvaquone Infected Macrophages and Is Highly Effective in a Murine Model","author":"Costa-Silva","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.intimp.2022.108952_b0225","doi-asserted-by":"crossref","unstructured":"E. Zijlstra, The immunology of post-kala-azar dermal leishmaniasis (PKDL), Paras ites and Vectors (2016). 10.1186\/s13071-016-1721-0.","DOI":"10.1186\/s13071-016-1721-0"},{"key":"10.1016\/j.intimp.2022.108952_b0230","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1093\/infdis\/jiy228","article-title":"Peripheral blood monocytes with an antiinflammatory phenotype display limited phagocytosis and oxidative burst in patients with visceral leishmaniasis","author":"Singh","year":"2018","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.intimp.2022.108952_b0235","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2016.00517","article-title":"Visceral leishmaniasis patients display altered composition and maturity of neutrophils as well as impaired neutrophil effector functions","author":"Yizengaw","year":"2016","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2022.108952_b0240","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1093\/infdis\/jir461","article-title":"IL-10 neutralization promotes parasite clearance in splenic aspirate cells from patients with visceral leishmaniasis","author":"Gautam","year":"2011","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.intimp.2022.108952_b0245","first-page":"8","article-title":"Role of CD8+ T cells in protection against Leishmania donovani infection in healed Visceral Leishmaniasis individuals","author":"Kaushal","year":"2014","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.intimp.2022.108952_b0250","first-page":"1","article-title":"Leishmania infantum Amastigotes Trigger a Subpopulation of Human B Cells with an Immunoregulatory Phenotype","author":"Andreani","year":"2015","journal-title":"PLoS Negl.Trop. Dis."},{"key":"10.1016\/j.intimp.2022.108952_b0255","first-page":"1","article-title":"Anti-parasite therapy drives changes in human visceral leishmaniasis-associated inflammatory balance","author":"Ara\u00fajo-Santos","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.intimp.2022.108952_b0260","first-page":"1","article-title":"A curative immune profile one week after treatment of Indian Kala-azar patients predicts success with a Short-course liposomal amphotericin B therapy","author":"Mondal","year":"2010","journal-title":"PlosS Neglected Tropical Diseases"},{"issue":"7","key":"10.1016\/j.intimp.2022.108952_b0265","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02507-18","article-title":"Systematic Review of Host-Mediated Activity of Miltefosine in Leishmaniasis through immunomodulation","volume":"63","author":"Pali\u0107","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.intimp.2022.108952_b0270","first-page":"1","article-title":"Lupeol induces immunity and protective efficacy in a murine model against visceral leishmaniasis","author":"Kaur","year":"2019","journal-title":"Parasitology"},{"key":"10.1016\/j.intimp.2022.108952_b0275","doi-asserted-by":"crossref","unstructured":"S.C.S. Petri e Silva, F. Palace-Berl, L.C. Tavares, R.S.C. Soares, J.A.L. Lindoso, Effects of nitro-heterocyclic derivatives against Leishmania (Leishmania) infantum promastigotes and intracellular amastigotes, Exp. Parasitol. (2016) 68-75. 10.1016\/j.exppara.2016.01.007.","DOI":"10.1016\/j.exppara.2016.01.007"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922004362?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922004362?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T18:00:34Z","timestamp":1761588034000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576922004362"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":55,"alternative-id":["S1567576922004362"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2022.108952","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pamidronate, a promising repositioning drug to treat leishmaniasis, displays antileishmanial and immunomodulatory potential","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2022.108952","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108952"}}